search icon
      blog search icon

      Why The Zynerba Pharmaceuticals (ZYNE) is Skyrocketing Today?

      By Fahim Awan

      Published on

      August 14, 2023

      7:11 PM UTC

      Why The Zynerba Pharmaceuticals (ZYNE) is Skyrocketing Today?

      Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) has soared vigorously in today’s market scenario, registering a notable ascension of 279.06% and reaching $1.28 today as per the most recent observations. The prior trading session, that is, Friday, witnessed the stabilization of Zynerba’s stock, demonstrating a modest uptick of 0.89% to culminate the day’s trade at $0.3390. This remarkable surge in ZYNE’s valuation can be attributed to a compelling takeover proposition that has materialized.

      Harmony Biosciences (Nasdaq: HRMY) has officially unveiled a definitive agreement, unveiling its strategic intent to acquire Zynerba Pharmaceuticals (ZYNE), a pharmaceutical entity specializing in rare neuropsychiatric ailments, prominently including Fragile X syndrome (FXS). Per the meticulously outlined stipulations within the definitive agreement, Harmony Biosciences will embark upon a decisive tender offer, poised to procure all outstanding shares of Zynerba at a stipulated purchase price of $1.1059 per share in hard currency.

      Alternatively, this amounts to an aggregate of $60 million, augmented by the inclusion of an exceptional non-negotiable contingent value right (CVR) appended to each share. Notably, this CVR extends the right to potential supplementary disbursements, capping at an aggregate sum of $140 million, subject to the achievement of specific clinical, regulatory, and commercial benchmarks.

      Elaborating upon the discrete milestones tethered to this acquisition framework:

      Clinical Attainments

      Successful culmination of FXS Phase 3 clinical trial: Yields an aggregate sum of $15 million or approximately $0.2747 per share.

      Positive data readout stemming from FXS Phase 3 clinical trial:

      • If realized by or on December 31, 2024: $30 million in total, equating to around $0.5494 per share.
      • If actualized prior to June 30, 2025: A total of $20 million, corresponding to approximately $0.3663 per share.
      • Post-June 30, 2025 accomplishment: Sum of $10 million, approximating $0.1831 per share.

      Regulatory Landmarks

      • Obtaining FDA endorsement for FXS: Sums up to $35 million in total or roughly $0.6389 per share.
      • Securing FDA approval for a Secondary Indication: Yields $15 million in aggregate, approximately $0.2707 per share.

      Net Sales Benchmarks

      • Reaching $250 million in aggregate Net Sales: Results in a total of $15 million or roughly $0.2702 per share.
      • Achieving $500 million in cumulative Net Sales: Translates to an aggregate sum of $30 million, approximating $0.5405 per share.

      Anticipated to conclude in the fourth quarter of 2023, this transaction hinges on customary closure prerequisites. Among these, a crucial condition involves the tendering of a majority of Zynerba’s outstanding shares by its stockholders to Harmony in conjunction with the tender offer. Subsequent to a triumphant tender offer culmination, Harmony Biosciences will finalize the acquisition of remaining Zynerba shares via a second-step merger at the same unit price specified in the initial tender offer. Zynerba’s board of directors, with unanimous consensus, urges its shareholders to participate in this tender offer.

      More From Stocks telegraph